Huaxi biological diving fell by more than 11%

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

CRM Software Provider EC Nets more than 100 Mn in Series D2

Business services are quietly changing. In the past, traditional CRM vendors have never been able to solve the problems of high costs of home-grown PaaS, long delivery cycles, and uncontrollable projects in the face of personalised enterprise needs. The new model of combining SaaS+PaaS will enable SaaS vendors to break out of the customisation trap.

China's Largest Cloud-based HCM Solution Provider Beisen Passed HKEx Hearing

On 20 March 2023, Beisen Holdings Limited(Chinese：北森控股） passed the HKSE hearing with Morgan Stanley and CICC as joint sponsors.

BOSS Zhipin Achieve Full Year Revenue of CNY 4,511 Mn in 2022，Net Profit Turns to Loss

Boosting employment is a key plan for China's economy in 2023. For now, there is still plenty of potential for online recruitment platforms to grow.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.